Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
AssigneeFordham University
InventorPramod K. Srivastava
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for enhancing immunological responses and for the prevention and treatment of infectious diseases or primary and metastatic neoplastic diseases based on the administration of macrophages and/or other antigen presenting cells (APC) sensitized with heat shock proteins non-covalently bound to peptide complexes and/or antigenic components. APC are incubated in the presence of hsp-peptide complexes and/or antigenic components in vitro. The sensitized cells are reinfused into the patient with or without treatment with cytokines including but not limited to interferon-.alpha., interferon-.alpha., interleukin-2, interleukin-4, interleukin-6 and tumor neurosis factor.
Claims29
A method of treating an individual having a type of cancer or metastasis comprising the steps of:
- (a) sensitizing antigen presenting cells in vitro with a sensitizing-effective amount of a purified complex of a heat shock protein noncovalently bound to an antigenic molecule, wherein said complex is obtained from or, said antigenic molecule is immunospecific to said type of cancer or metastasis;
- and
- (b) administering to an individual having said type of cancer or metastasis a therapeutically effective amount of the sensitized antigen presenting cells.
A method of treating an individual having a type of cancer or metastasis comprising administering to the individual a therapeutically effective amount of sensitized antigen presenting cells, in which the antigen presenting cells have been sensitized in vitro with a purified complex of a heat shock protein noncovalently bound to an antigenic molecule, wherein said complex is obtained from or, said antigenic molecule is immunospecific to said type of cancer or metastasis.
A pharmaceutical composition comprising a therapeutically effective amount of sensitized antigen presenting cells, in a pharmaceutically acceptable carrier, in which the antigen presenting cells have been sensitized in vitro with a purified complex of a heat shock protein noncovalently bound to an antigenic molecule, wherein said complex is obtained from or, said antigenic molecule is immunospecific to a type of cancer or metastasis.
A method of inhibiting growth of a type of cancer or metastasis in an individual in whom such inhibition is desired comprising the steps of:
- (a) sensitizing antigen presenting cells in vitro with a sensitizing-effective amount of a purified complex of a heat shock protein noncovalently bound to an antigenic molecule, wherein said complex is obtained from or, said antigenic molecule is immunospecific to said type of cancer or metastasis;
- and
- (b) administering a therapeutically effective amount of the sensitized antigen presenting cells to an individual in whom inhibition of growth of said type of cancer or metastasis is desired.
A method of inhibiting growth of a type of cancer or metastasis in an individual in whom such inhibition is desired comprising administering to the individual a therapeutically effective amount of sensitized antigen presenting cells, in which the antigen presenting cells have been sensitized in vitro with a purified complex of a heat shock protein noncovalently bound to an antigenic molecule, wherein said complex is obtained from or, said antigenic molecule is immunospecific to said type of cancer or metastasis.
Dependencies are inferred from the claim text.